Funding momentum CDT recently secured $10M in seed and early-stage financing, signaling investor confidence and potential for scaled project support, which could translate into expanded collaboration opportunities and higher-value contracts.

Strategic acquisitions Historical acquisition by Aclaris Therapeutics and ongoing ties suggest CDT may navigate partnerships and potential integration with larger pharma structures, presenting a path for co-development agreements or exit-ready collaboration models.

Early discovery focus CDT specializes in early-stage drug discovery and development across biochemistry, cellular biology, immunology, and translational biomarkers, aligning with biotech startups and mid-sized pharma seeking comprehensive upfront discovery services.

US-based expertise Located in Saint Louis with a full-service lab and a broad technical stack, CDT offers domestic collaboration with potential accelerators and grants-friendly partners looking for compliant, rapid-turnaround early research support.

Moderate scale fit With 11-50 employees and revenue in the mid-range, CDT is positioned to partner with mid-sized biotech firms and specialty CRO buyers who require flexible engagement models and cost-effective early discovery services.